Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.
Launch of Myeloma BioBank
The Exciting Launch of Myeloma BioBank: James R. Berenson, MD, Multiple Myeloma, specialist announced in an interview...